{"component": "definition", "props": {"groups": [{"samples": [{"hash": "iNML0Typ0I0", "uri": "/contracts/iNML0Typ0I0#third-party-collaborator", "label": "Terms of Service", "score": 32.1913461684, "published": true}, {"hash": "eOrplX7ruGx", "uri": "/contracts/eOrplX7ruGx#third-party-collaborator", "label": "Terms of Service", "score": 31.6492995585, "published": true}, {"hash": "7ooKwe42kJl", "uri": "/contracts/7ooKwe42kJl#third-party-collaborator", "label": "Terms of Service", "score": 31.6328739036, "published": true}], "snippet_links": [{"key": "unaffiliated-third-party", "type": "definition", "offset": [9, 33]}, {"key": "a-third-party", "type": "clause", "offset": [85, 98]}, {"key": "enterprise-customer", "type": "definition", "offset": [127, 146]}, {"key": "the-service", "type": "clause", "offset": [150, 161]}, {"key": "personal-user", "type": "definition", "offset": [167, 180]}], "snippet": "means an unaffiliated third party that Customer invites to participate on a Project. A Third Party Collaborator may be another enterprise customer of the Service or a Personal User.", "size": 4, "hash": "01d0b9c298c680a704b4fba3cfd9b2d7", "id": 1}, {"samples": [{"hash": "9U1NXUCS7Sl", "uri": "/contracts/9U1NXUCS7Sl#third-party-collaborator", "label": "License Agreement (Voyager Therapeutics, Inc.)", "score": 26.839835729, "published": true}, {"hash": "9AkWvIao9L7", "uri": "/contracts/9AkWvIao9L7#third-party-collaborator", "label": "License Agreement (Voyager Therapeutics, Inc.)", "score": 26.7686516085, "published": true}, {"hash": "lMPIck3wDoA", "uri": "/contracts/lMPIck3wDoA#third-party-collaborator", "label": "License Agreement (Voyager Therapeutics, Inc.)", "score": 26.5496235455, "published": true}], "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [6, 19]}, {"key": "entered-into", "type": "clause", "offset": [43, 55]}, {"key": "disease-indication", "type": "definition", "offset": [89, 107]}, {"key": "research-and-development-activities", "type": "definition", "offset": [124, 159]}, {"key": "during-the-research-term", "type": "clause", "offset": [196, 220]}, {"key": "of-licensee", "type": "clause", "offset": [237, 248]}, {"key": "specified-vector", "type": "clause", "offset": [288, 304]}, {"key": "commercial-option", "type": "clause", "offset": [330, 347]}, {"key": "the-third-party", "type": "definition", "offset": [400, 415]}, {"key": "exercise-of", "type": "clause", "offset": [455, 466]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [516, 542]}, {"key": "right-to-conduct", "type": "clause", "offset": [621, 637]}, {"key": "this-exhibit", "type": "definition", "offset": [784, 796]}, {"key": "replaced-with", "type": "clause", "offset": [814, 827]}, {"key": "the-secretary", "type": "clause", "offset": [903, 916]}, {"key": "the-securities-and-exchange-commission", "type": "clause", "offset": [920, 958]}, {"key": "pursuant-to", "type": "definition", "offset": [959, 970]}, {"key": "confidential-treatment", "type": "clause", "offset": [997, 1019]}, {"key": "under-rule", "type": "clause", "offset": [1020, 1030]}, {"key": "securities-act-of-1933", "type": "clause", "offset": [1057, 1079]}, {"key": "as-amended", "type": "definition", "offset": [1081, 1091]}], "snippet": "means a Third Party with whom Licensee has entered into a collaboration for a particular Disease Indication under which (a) research and development activities will be performed on a shared basis during the Research Term for the purpose of Licensee and such Third Party determining which Specified Vector would be selected if the Commercial Option for such Disease Indication were exercised, and (b) the Third Party will be granted commercial rights upon exercise of a Commercial Option for such Disease Indication. For the avoidance of doubt, a Third Party Collaborator will not include a Third Party who is granted the right to conduct research and development activities independent of Licensee or unrelated to the exercise of a Commercial Option. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.", "size": 3, "hash": "ffd0994d602f7eedec74d373162c1ada", "id": 2}, {"samples": [{"hash": "j1hTXpK4PVH", "uri": "/contracts/j1hTXpK4PVH#third-party-collaborator", "label": "Grant Disbursement Agreement", "score": 30.0775588665, "published": true}, {"hash": "zUOxfXjP3g", "uri": "/contracts/zUOxfXjP3g#third-party-collaborator", "label": "Grant Disbursement Agreement", "score": 29.6285909674, "published": true}, {"hash": "lCybddCTrq2", "uri": "/contracts/lCybddCTrq2#third-party-collaborator", "label": "Grant Disbursement Agreement", "score": 29.3411420076, "published": true}], "snippet_links": [{"key": "the-partner", "type": "clause", "offset": [43, 54]}, {"key": "grant-recipient", "type": "definition", "offset": [58, 73]}, {"key": "the-sub", "type": "clause", "offset": [90, 97]}], "snippet": "Any organisation or individual who are not the Partner or Grant Recipient contributing to the Sub-project.", "size": 3, "hash": "59413f2860d95707618ae11aa555566f", "id": 3}, {"samples": [{"hash": "hARjuTQMGM4", "uri": "/contracts/hARjuTQMGM4#third-party-collaborator", "label": "Collaboration Agreement (Mersana Therapeutics, Inc.)", "score": 28.4140999316, "published": true}, {"hash": "ex9b4q7MAZv", "uri": "/contracts/ex9b4q7MAZv#third-party-collaborator", "label": "Collaboration Agreement (Mersana Therapeutics, Inc.)", "score": 28.2060232717, "published": true}], "snippet_links": [{"key": "section-31", "type": "clause", "offset": [25, 36]}], "snippet": "has the meaning given in Section 3.1.", "size": 2, "hash": "f9a1626db651263dca4a086ecd5a7867", "id": 4}, {"samples": [{"hash": "kqQ8o8Ag7z", "uri": "/contracts/kqQ8o8Ag7z#third-party-collaborator", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 28.2169746749, "published": true}, {"hash": "kR0zphdkFnb", "uri": "/contracts/kR0zphdkFnb#third-party-collaborator", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 27.8199863107, "published": true}], "snippet_links": [{"key": "third-party", "type": "clause", "offset": [10, 21]}, {"key": "entered-into", "type": "clause", "offset": [44, 56]}, {"key": "an-agreement", "type": "clause", "offset": [57, 69]}, {"key": "amended-effective-date", "type": "definition", "offset": [80, 102]}, {"key": "for-purposes-of", "type": "clause", "offset": [103, 118]}, {"key": "natural-compounds", "type": "definition", "offset": [150, 167]}, {"key": "intended-for-use", "type": "definition", "offset": [177, 193]}, {"key": "product-categories", "type": "definition", "offset": [232, 250]}], "snippet": "means any Third Party with whom SENOMYX has entered into an agreement after the Amended Effective Date for purposes of discovering or commercializing Natural Compounds that are intended for use as a sweetener and/or enhancer in all product categories.", "size": 2, "hash": "a92f1650751b8972e015b6f54d06426c", "id": 5}, {"samples": [{"hash": "lfDJ5wa7Mla", "uri": "/contracts/lfDJ5wa7Mla#third-party-collaborator", "label": "Collaboration Agreement (BioNTech SE)", "score": 30.6865160849, "published": true}, {"hash": "19xhXAM9aZU", "uri": "/contracts/19xhXAM9aZU#third-party-collaborator", "label": "Collaboration Agreement (BioNTech SE)", "score": 30.5906913073, "published": true}], "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [6, 19]}], "snippet": "means a Third Party [***]", "size": 2, "hash": "ad053e27a9e411cb36b2d6397deaa2bc", "id": 6}, {"samples": [{"hash": "gB8kfY3Kz6C", "uri": "/contracts/gB8kfY3Kz6C#third-party-collaborator", "label": "Strategic Collaboration Agreement (Nektar Therapeutics)", "score": 29.3531827515, "published": true}, {"hash": "cCp3KT0uDYx", "uri": "https://ir.nektar.com/static-files/fff0f320-3c22-4fc9-9a44-5187d8fc10a2", "label": "ir.nektar.com", "score": 10.1704312115, "published": false}], "snippet_links": [{"key": "third-party", "type": "clause", "offset": [10, 21]}, {"key": "with-respect-to", "type": "clause", "offset": [34, 49]}, {"key": "a-party", "type": "clause", "offset": [81, 88]}, {"key": "the-development", "type": "clause", "offset": [92, 107]}], "snippet": "means any Third Party (including, with respect to BMS, Ono) that is engaged with a Party in the Development or Commercialization of any Nektar Asset or BMS Asset, as applicable.", "size": 2, "hash": "30885764e6dd765d41e72c00529eb0cb", "id": 7}, {"samples": [{"hash": "fvNeBetntpk", "uri": "/contracts/fvNeBetntpk#third-party-collaborator", "label": "License Agreement (REGENXBIO Inc.)", "score": 26.7029431896, "published": true}, {"hash": "c2iT2yC3vRL", "uri": "/contracts/c2iT2yC3vRL#third-party-collaborator", "label": "License Agreement (REGENXBIO Inc.)", "score": 26.6235455168, "published": true}], "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [6, 19]}, {"key": "entered-into", "type": "clause", "offset": [43, 55]}, {"key": "disease-indication", "type": "definition", "offset": [89, 107]}, {"key": "research-and-development-activities", "type": "definition", "offset": [124, 159]}, {"key": "during-the-research-term", "type": "clause", "offset": [196, 220]}, {"key": "of-licensee", "type": "clause", "offset": [237, 248]}, {"key": "specified-vector", "type": "clause", "offset": [288, 304]}, {"key": "commercial-option", "type": "clause", "offset": [330, 347]}, {"key": "the-third-party", "type": "definition", "offset": [400, 415]}, {"key": "exercise-of", "type": "clause", "offset": [455, 466]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [516, 542]}, {"key": "right-to-conduct", "type": "clause", "offset": [621, 637]}], "snippet": "means a Third Party with whom Licensee has entered into a collaboration for a particular Disease Indication under which (a) research and development activities will be performed on a shared basis during the Research Term for the purpose of Licensee and such Third Party determining which Specified Vector would be selected if the Commercial Option for such Disease Indication were exercised, and (b) the Third Party will be granted commercial rights upon exercise of a Commercial Option for such Disease Indication. For the avoidance of doubt, a Third Party Collaborator will not include a Third Party who is granted the right to conduct research and development activities independent of Licensee or unrelated to the exercise of a Commercial Option.", "size": 2, "hash": "bee09f9c981ee339a3e656eb68bd9e5a", "id": 8}, {"samples": [{"hash": "jsiGv4986tf", "uri": "/contracts/jsiGv4986tf#third-party-collaborator", "label": "License Agreement (Centessa Pharmaceuticals LTD)", "score": 32.3018480493, "published": true}], "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [6, 19]}, {"key": "entered-into", "type": "clause", "offset": [29, 41]}, {"key": "written-agreement", "type": "definition", "offset": [44, 61]}, {"key": "licensed-product", "type": "clause", "offset": [153, 169]}, {"key": "of-licensee", "type": "clause", "offset": [189, 200]}], "snippet": "means a Third Party that has entered into a written agreement with Licensee to conduct research. development, manufacture, and/or commercialization of a Licensed Product with, or on behalf of Licensee", "size": 2, "hash": "c813636c1e32d5fac25bcc5c822e37c3", "id": 9}, {"samples": [{"hash": "8WAmlNsY5ya", "uri": "/contracts/8WAmlNsY5ya#third-party-collaborator", "label": "Antibody Discovery and Option Agreement (ARCA Biopharma, Inc.)", "score": 35.4613278576, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 2.1(c).", "size": 1, "hash": "f2b079d00203f9632c97707b17e886e2", "id": 10}], "next_curs": "CmUSX2oVc35sYXdpbnNpZGVyY29udHJhY3RzckELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIhdGhpcmQtcGFydHktY29sbGFib3JhdG9yIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Third Party Collaborator", "snippet": "means an unaffiliated third party that Customer invites to participate on a Project. A Third Party Collaborator may be another enterprise customer of the Service or a Personal User.", "size": 24, "id": "third-party-collaborator", "examples": ["If a <strong>Third Party Collaborator</strong> is not a customer of the Service that has agreed to this Agreement and created its own account, then such <strong>Third Party Collaborator</strong> will not be able to access any Project.", "In addition, a <strong>Third Party Collaborator</strong> may utilize assays developed by OSI using CADUS Technology to test compounds solely during the term and in furtherance of its collaboration with OSI.", "Both Parties shall work together in good faith to develop a work plan that meets the needs of the applicable <strong>Third Party Collaborator</strong>.", "For example, it is anticipated that Mersana may choose to grant a <strong>Third Party Collaborator</strong> exclusivity around the use of Fleximer, Linker and a Payload (or any such components) with respect to [***] Target, but that Adimab would not grant such <strong>Third Party Collaborator</strong> exclusivity with respect to Antibodies against [***] Target (other than the specific Antibodies discovered and optimized pursuant to the Third Party Collaboration).", "OSI shall not provide any Covered Material to any Third Party other than a contract research organization or <strong>Third Party Collaborator</strong> that has executed a confidentiality agreement with respect to the Covered Material containing provisions similar to Section 10 hereof.", "Each Party shall be entitled to receive [***] of all proceeds from a <strong>Third Party Collaborator</strong> under each Third Party Collaboration, as set forth in more detail in the Third Party Collaboration Term Sheet.", "However, subject to the first sentence of this Section 3.3(b), the Parties agree that, under the terms of the Third Party Collaboration, the <strong>Third Party Collaborator</strong> shall have the right to terminate the Third Party Collaboration at its convenience.", "Each final agreement with each <strong>Third Party Collaborator</strong> must be approved by both Parties prior to execution and, subject to Sections 3.3(b) and 3.8(d), neither Party will enter into a two-party Third Party Collaboration agreement without the written consent of the other Party; provided, however, that a Party may not withhold approval regarding any term in the Third Party Collaboration Term Sheet.", "Unless otherwise agreed to by the Parties, all other costs of Third Party Collaborations that are not paid for by the applicable <strong>Third Party Collaborator</strong> shall be borne [***], except that all costs relating to patent prosecution shall be divided as set forth in ARTICLE 7 of this Agreement, to the extent addressed therein.", "On a case-by-case basis, the Parties, through the Business Representatives, shall mutually agree on which of Adimab or Mersana shall be responsible for leading the negotiations of a Third Party Collaboration agreement with each potential <strong>Third Party Collaborator</strong>, which agreement will, unless otherwise agreed by both Business Representatives, be a three-party agreement between Adimab, Mersana, and such <strong>Third Party Collaborator</strong>."], "related": [["third-party-ipr", "Third Party IPR", "Third Party IPR"], ["third-party-ip", "Third Party IP", "Third Party IP"], ["third-party-technology", "Third Party Technology", "Third Party Technology"], ["collaboration-patent-rights", "Collaboration Patent Rights", "Collaboration Patent Rights"], ["third-party-licensor", "Third Party Licensor", "Third Party Licensor"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}